focus -WSS

focus

author：fashion 2025-09-27 12:36:36 - browse：18

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Why you shouldn’t ask, “What country has the best health care?”

WSS

Why you shouldn’t ask, “What country has the best health care?”

Medicare drug price negotiation legal challenge met with skepticism

#NeedHerScience: shining a light on gender disparities in medicine

Disclosing genetic information: not as worrisome as once feared

How generative AI ratchets up security threats for health systems

Biogen walks away from Aduhelm, years after polarizing approval

entertainment

focus

entertainment

Anesthesiologist group: stop taking Ozempic before surgery

Donald Trump's relentless attacks on special counsel Jack Smith

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

In areas with more Black doctors, Black people live longer

Medical leaders decry Supreme Court decision on affirmative action

Medicare Advantage insurers face 0.2% cut to 2025 payments

After affirmative action ruling, medical educators look to 'holistic review'

Merck, Johnson & Johnson CEOs will testify on high drug prices

Dobbs anniversary: the lost opportunity of abortion as health care

The story of mRNA: From a loose idea to a tool that may help curb Covid

focus

10 reasons why health care startups fail

With FDA staff opposed to Sarepta therapy, top official intervened

10 reasons why health care startups fail

Wegovy leads to weight loss. Can it treat depression, too?

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Donald Trump's relentless attacks on special counsel Jack Smith

entertainment

hotspot

hotspot

focus